Editorial Material
Health Care Sciences & Services
Gary S. Donovitz
Summary: Hormone replacement therapy, particularly the use of testosterone in women, continues to be controversial in medicine. However, there is growing evidence to support the use of physiologic doses of testosterone to improve sexual function, prevent osteoporosis, protect the brain, and reduce the incidence of invasive breast cancer in women. The safety of testosterone use in women has been evaluated for 80 years, with recent studies showing long-term safety. It may be time for the FDA to consider approving products that would benefit testosterone-deficient women.
JOURNAL OF PERSONALIZED MEDICINE
(2022)
Article
Multidisciplinary Sciences
Wei-Chuan Chang, Jen-Hung Wang, Dah-Ching Ding
Summary: This study found that in postmenopausal women in Taiwan, hormone therapy with oral conjugated equine estrogen (CEE) may be associated with a higher risk of ischemic stroke (IS) compared to estradiol (E2), especially when initiated within 5 years of menopause.
SCIENTIFIC REPORTS
(2021)
Review
Endocrinology & Metabolism
Lawrence M. Nelson, Hillary Spencer, Karima Hijane, Payom Thinuan, Chaninan W. Nelson, Amanda J. Vincent, Catherine M. Gordon, Tony M. Plant, Pouneh K. Fazeli
Summary: Closing the gap between knowledge and action in healthcare is necessary. The advancement of global internet and mobile communication enables the possibility of innovative digital health education platforms and care delivery. The establishment of a global digital medical hub focused on women's health and secondary amenorrhea can improve information integration and exchange processes, benefiting patients, caregivers, providers, and researchers.
FRONTIERS IN ENDOCRINOLOGY
(2023)
Article
Chemistry, Medicinal
Guilherme Renke, Francisco Tostes
Summary: We discussed the CV safety and efficacy of subcutaneous testosterone therapy (STT) in postmenopausal women. Our proposed innovative criteria (IDEALSTT) for recommending STT include total testosterone level, carotid artery intima-media thickness, and calculated SCORE for 10-year CVD risk. While hormone replacement therapy (HRT) with testosterone has gained popularity in treating pre and postmenopausal women, the long-term safety and CV risk of STT in women are still controversial.
Review
Obstetrics & Gynecology
J. M. Nielsen, P. Humaidan, M. B. Jensen, B. Alsbjerg
Summary: Bleeding before the eighth week of gestation is common in HRT-FET patients, but does not affect reproductive outcomes. Spontaneously conceived pregnancies have a 20% incidence of bleeding, most of which have normal outcomes.
HUMAN REPRODUCTION
(2023)
Article
Geriatrics & Gerontology
Romane Lemarechal, Sara Hoummady, Ines Barthelemy, Claude Muller, Julie Hua, Caroline Gilbert, Loic Desquilbet
Summary: Frailty is a clinical condition resulting from age-related declines in multiple physiological systems. This study aimed to adapt the concept of frailty to dogs and investigate its association with death. Using a 5-criterion frailty phenotype, frail dogs had significantly higher risk of death compared to nonfrail dogs, with median survival times of 10.5 months, 35.4 months, and 42.5 months for dogs with 3 or more criteria, prefrail dogs, and nonfrail dogs, respectively.
JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES
(2023)
Article
Endocrinology & Metabolism
Bradley S. Miller, Joanne C. Blair, Michael Hojby Rasmussen, Aristides Maniatis, Jun Mori, Volker Boettcher, Ho-Seong Kim, Rikke Beck Bang, Michel Polak, Reiko Horikawa
Summary: This study evaluated the efficacy and tolerability of somapacitan in children with growth hormone deficiency (GHD) for 2 years and after switching from daily growth hormone treatment. The results showed that somapacitan was effective and well-tolerated during the 2-year period, and patients and caregivers preferred once-weekly somapacitan treatment.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2023)
Review
Endocrinology & Metabolism
Clara Born, Franz Jakob, Mahdieh Shojaa, Matthias Kohl, Simon von Stengel, Katharina Kerschan-Schindl, Uwe Lange, Friederike Thomasius, Wolfgang Kemmler
Summary: This study aimed to determine whether enhancing hormone therapy (HT) with exercise increases the effect of HT on bone mineral density. The results showed that the addition of exercise did not significantly enhance the effect of HT on bone density at the lumbar spine and femoral neck.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2022)
Review
Geriatrics & Gerontology
Bogdan Stefanowski, Marek Kucharski, Anna Szeliga, Milena Snopek, Anna Kostrzak, Roman Smolarczyk, Marzena Maciejewska-Jeske, Anna Duszewska, Olga Niwczyk, Slawomir Drozd, Monika Englert-Golon, Katarzyna Smolarczyk, Blazej Meczekalski
Summary: Globally, cognitive decline and dementia pose a major challenge to public health. The causes of these conditions can be genetic or triggered by various factors. The association between estrogen decline after menopause and cognitive decline/dementia remains inconclusive. This article explores the prevention of cognitive decline and dementia in postmenopausal women, focusing on pharmacological intervention for primary prevention and diet/weight reduction for secondary prevention. Further research is needed to determine the role of menopausal hormone therapy (MHT) in dementia.
Article
Medicine, General & Internal
Zi-Han Li, Lu-Jia Ni, Yuan-Qiao Liu, Dao-Yuan Si
Summary: This article reports a case of a young male who rapidly developed hypothyroid cardiomyopathy secondary to radioactive iodine treatment, suggesting that severe heart failure can occur even after a short period of hypothyroidism.
WORLD JOURNAL OF CLINICAL CASES
(2023)
Article
Medicine, General & Internal
Jaehoon Lee, Yuntae Kim, Hyunji Park, Changsoo Kim, Sihyun Cho, Jongyoun Kim
Summary: This study investigated the association between different types of hormone replacement therapy (HRT) and atrial fibrillation (AF). The findings showed that current HRT users, except those using estradiol-only HRT, had significantly elevated AF risk, while past users who used estradiol plus progestin HRT had a reduced AF risk.
JOURNAL OF CLINICAL MEDICINE
(2021)
Review
Biochemistry & Molecular Biology
Guilherme Renke, Consuelo Callizo, Raphaela Paes, Mariana Antunes, Glaycon Michels, Luana Concha, Ordanio Almeida, Christiane Valente, Thomaz Baesso, Bruna Giovannoni
Summary: Segesterone acetate (SA) or Nestorone, a fourth-generation progestogen, is a synthetic compound with high progestational activity. It is used in female contraception and postmenopausal hormone replacement therapy (HRT), and has potential uses in endometriosis, polycystic ovaries syndrome (PCOS), and neuroprotection. However, the standardized dose and long-term safety of SA implant therapy in women are still controversial.
Article
Endocrinology & Metabolism
Tessa N. A. Slagboom, Christa C. van Bunderen, Aart Jan van der Lely, Madeleine L. Drent
Summary: This study investigated the differences in the outcomes of growth hormone replacement therapy (GHRT) between growth hormone deficient (GHD) men and women. The results showed that women were more likely to have subnormal insulin-like growth factor-1 (IGF-1) levels during treatment and experienced more adverse events, requiring dose reduction or temporary stoppage of GHRT. Men had a higher risk of developing malignant neoplasms. This suggests that women with GHD may not be receiving optimal treatment and have lower tolerability of GHRT, but it does not imply discontinuation of treatment.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2023)
Article
Pharmacology & Pharmacy
Wen-Hsuan Tsai, Fung-Chang Sung, Chih-Hsin Muo, Ming-Chieh Tsai, Shu-I. Wu
Summary: Patients with osteoporosis have increased risk of cardiovascular disease (CVD). Some antiosteoporosis medications may have protective effects against CVD, with denosumab, teriparatide, and bisphosphonate showing lower risks compared to hormone therapy. Physicians should consider cardiovascular risks when prescribing antiosteoporosis medication for osteoporosis patients.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Clinical Neurology
Hyewon Kim, Juhwan Yoo, Kyungdo Han, Dong-Yun Lee, Maurizio Fava, David Mischoulon, Hong Jin Jeon
Summary: This study investigated the association between hormone therapy and the occurrence of dementia in female patients with depression. The findings showed that lifetime oral contraceptive use was associated with a decreased risk of Alzheimer's disease (AD), and hormone replacement therapy after menopause was associated with a decreased risk of AD and vascular dementia (VD) among female patients with depression.
ALZHEIMERS RESEARCH & THERAPY
(2022)